These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 20495135)

  • 21. Development of a population pharmacokinetics-based sampling schedule to target daily intravenous busulfan for outpatient clinic administration.
    Salinger DH; Vicini P; Blough DK; O'Donnell PV; Pawlikowski MA; McCune JS
    J Clin Pharmacol; 2010 Nov; 50(11):1292-300. PubMed ID: 20075185
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Limited sampling strategies for predicting area under the concentration-time curve of mycophenolic acid in islet transplant recipients.
    Al-Khatib M; Shapiro RJ; Partovi N; Ting LS; Levine M; Ensom MH
    Ann Pharmacother; 2010 Jan; 44(1):19-27. PubMed ID: 19996322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Moclobemide: evolution, pharmacodynamic, and pharmacokinetic properties.
    Bonnet U
    CNS Drug Rev; 2002; 8(3):283-308. PubMed ID: 12353059
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of moclobemide after single and multiple oral dosing with 150 milligrams 3 times daily for 15 days.
    Guentert TW; Tucker G; Korn A; Pfefen JP; Haefelfinger P; Schoerlin MP
    Acta Psychiatr Scand Suppl; 1990; 360():91-3. PubMed ID: 2248087
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential of concentration monitoring data for a short half-life drug: analysis of pharmacokinetic variability for moclobemide.
    Gex-Fabry M; Balant-Gorgia AE; Balant LP
    Ther Drug Monit; 1995 Feb; 17(1):39-46. PubMed ID: 7725375
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of activated charcoal versus gastric lavage half an hour after ingestion of moclobemide, temazepam, and verapamil.
    Lapatto-Reiniluoto O; Kivistö KT; Neuvonen PJ
    Eur J Clin Pharmacol; 2000 Jul; 56(4):285-8. PubMed ID: 10954340
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cimetidine alters the disposition kinetics of the monoamine oxidase-A inhibitor moclobemide.
    Schoerlin MP; Mayersohn M; Hoevels B; Eggers H; Dellenbach M; Pfefen JP
    Clin Pharmacol Ther; 1991 Jan; 49(1):32-8. PubMed ID: 1988238
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Moclobemide poisoning: toxicokinetics and occurrence of serotonin toxicity.
    Isbister GK; Hackett LP; Dawson AH; Whyte IM; Smith AJ
    Br J Clin Pharmacol; 2003 Oct; 56(4):441-50. PubMed ID: 12968990
    [TBL] [Abstract][Full Text] [Related]  

  • 29. No influence of body weight on serum levels of antidepressants.
    Unterecker S; Deckert J; Pfuhlmann B
    Ther Drug Monit; 2011 Dec; 33(6):730-4. PubMed ID: 22105590
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of food intake on the relative bioavailability of moclobemide (Ro 11-1163).
    Schoerlin MP; Mayersohn M; Hoevels B; Eggers H; Dellenbach M; Pfefen JP
    J Neural Transm Suppl; 1988; 26():115-21. PubMed ID: 3283288
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TK Modeler version 1.0, a Microsoft® Excel®-based modeling software for the prediction of diurnal blood/plasma concentration for toxicokinetic use.
    McCoy AT; Bartels MJ; Rick DL; Saghir SA
    Regul Toxicol Pharmacol; 2012 Jul; 63(2):333-43. PubMed ID: 22504463
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disposition kinetics of moclobemide, a monoamine oxidase-A enzyme inhibitor: single and multiple dosing in normal subjects.
    Schoerlin MP; Mayersohn M; Korn A; Eggers H
    Clin Pharmacol Ther; 1987 Oct; 42(4):395-404. PubMed ID: 3665338
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Limited Sampling Strategy for Accurate Prediction of Pharmacokinetics of Saroglitazar: A 3-point Linear Regression Model Development and Successful Prediction of Human Exposure.
    Joshi SN; Srinivas NR; Parmar DV
    Clin Ther; 2018 Mar; 40(3):456-468.e1. PubMed ID: 29496320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Pharmacokinetics and metabolism of reversible MAO-A inhibitors in the human].
    Schoerlin MP; Guentert TW
    Psychiatr Prax; 1989 Aug; 16 Suppl 1():11-7. PubMed ID: 2685852
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Antidepressant pharmacokinetics during pregnancy].
    Maslovskiĭ SIu
    Eksp Klin Farmakol; 2013; 76(1):14-20. PubMed ID: 23461010
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Applicability of a Single Time Point Strategy for the Prediction of Area Under the Concentration Curve of Linezolid in Patients: Superiority of Ctrough- over Cmax-Derived Linear Regression Models.
    Srinivas NR; Syed M
    Drugs R D; 2016 Mar; 16(1):69-79. PubMed ID: 26747454
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Moclobemide excretion in human breast milk.
    Pons G; Schoerlin MP; Tam YK; Moran C; Pfefen JP; Francoual C; Pedarriosse AM; Chavinie J; Olive G
    Br J Clin Pharmacol; 1990 Jan; 29(1):27-31. PubMed ID: 2297459
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Personalized Tuberculosis Treatment Through Model-Informed Dosing of Rifampicin.
    van Beek SW; Ter Heine R; Keizer RJ; Magis-Escurra C; Aarnoutse RE; Svensson EM
    Clin Pharmacokinet; 2019 Jun; 58(6):815-826. PubMed ID: 30671890
    [TBL] [Abstract][Full Text] [Related]  

  • 39. How 'Optimal' are Optimal Sampling Times for Tyrosine Kinase Inhibitors in Cancer? Practical Considerations.
    Ward MB; Reuter SE; Martin JH
    Clin Pharmacokinet; 2016 Oct; 55(10):1171-1177. PubMed ID: 27085335
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The pharmacokinetic profile of RS-8359.
    Püchler K; Sasahara K; Plenker A; Nitanai T; Witte PU
    Int Clin Psychopharmacol; 1997 Sep; 12 Suppl 5():S11-6. PubMed ID: 9466164
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.